Clinical evaluation of contrast medium and cardiac function in the patients with cardio-renal syndrome by minimally-invasive hemodynamic monitoring method

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13003477

Enrollment

Unknown

Registered

2013-07-14

Start date

2013-07-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary atherosclerotic heart disease

Interventions

iso-osmolar contrast medium group:give iso-osmolar contrast medium (Iodixanol)

low-osmolar contrast medium group:give low-osmolar contrast medium (Iopromide)

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with chronic heart failure: (1) With previous clinical symptoms of chronic heart failure: exertional dyspnea, paroxysmal nocturnal dyspnea, orthopnea; (2) Or present objective lab evidences of heart failure, such as: Echocardiography (LEVF = 500 pg/ml; 2. Patients plan to undergo PCI treatment; 3. Patients with CKD (eGFR<60ml/min); Note: Heart failure is defined, clinically, as a syndrome in which patients have typical symptoms (e.g. breathlessness, ankle swelling, and fatigue) and signs (e.g. elevated jugular venous pressure, pulmonary crackles, and displaced apex beat) resulting from an abnormality of cardiac structure or function. (ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012).

Exclusion criteria

Exclusion criteria: 1. renal failure patients (eGFR<30ml/min); 2. Patients with known hypersensitivity to contrast media; 3. Patients with malignant, severe hepatic and renal failure, respiratory failure or other diseases for which the investigator considered the patient could not be included (including epilepsy); 4. Patient complicated with severe short-term progressive disease; 5. Patients with manifest thyrotoxicosis or other contraindications to Visipaque or Ultravist 6. Patients < 18 years; 7. Patients with acute myocardial infarction; 8. Patients with heart failure due to valvular disease and structural heart disease; 9. Patients with malignant arrhythmias; 10. Patients with implants like pacemakers, LVAD, Eject fraction <30%,etc; 11. Patients with contrast examination in previous 7 days.

Design outcomes

Primary

Measure	Time frame
Extravascular Lung Water Index (EVLWI);	—

Secondary

Measure	Time frame
Cardiac index (CI);Global End-diastolic Index (GEDI);	—

Countries

China

Contacts

Public ContactYun-dai CHEN

cyundai@126.com+86 13311119778

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026